

HHS/ASPR COVID-19 Outpatient Therapeutics Mini-Series
Session #5— Managing Infusion Reactions
Wednesday, January 27, 2021 (12-1 PM ET)
Meet the Faculty

Our Panelists:

Mariana Castells, MD, PhD	2
<i>Director, Drug Hypersensitivity and Desensitization Center, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School; Boston, MA</i>	
Mark P. Jarrett, MD, MBA, MS	3
<i>Senior Vice President and Chief Quality Officer, Northwell Health; Deputy Chief Medical Officer, Northwell Health; Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; East Garden City, NY.....</i>	
Michael D. Keller, MD	4
<i>Associate Professor, Division of Allergy / Immunology; Director, Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency Disorders; Washington, DC.....</i>	
Nancy Kramer RN, BSN, CRNI	4
<i>VP Clinical Nursing, Optum Infusion Services; Lenexa, KS.....</i>	
Madhumita Murphy, MD, MSCI, MBA.....	5
<i>Senior Medical Advisor, Eli Lilly and Company; Franklin, TN.....</i>	
Ernesto Oviedo-Orta, MD, PhD, MBA.....	5
<i>Senior Director, Medical Affairs, Regeneron Pharmaceuticals, Inc.; Tarrytown, NY.....</i>	

Mariana Castells, MD, PhD

***Director, Drug Hypersensitivity and Desensitization Center, Brigham and Women's Hospital;
Professor of Medicine, Harvard Medical School; Boston, MA***



Mariana Castells, M.D., Ph.D. is a clinician, researcher and teacher at Brigham and Women's Hospital and Dana Farber Cancer Institute. She is the Director of the Drug Hypersensitivity and Drug Desensitization Center and of the Mastocytosis Center and has served as the Allergy and Clinical Immunology Training Program Director for over 20 years.

Dr Castells has spearheaded the evaluation and understanding of anaphylaxis and drug hypersensitivity and has developed desensitization protocols which are used as standards around the world, treating thousands of patients with cancer and chronic inflammatory diseases, maintaining these patients on first line therapy. She sees and treat patients with drug allergy, anaphylaxis, mast cell activation disorders, urticaria, immune deficiencies, regular food and environmental allergies and asthma.

Her research has uncovered mast cell inhibitory mechanisms which are pertinent to desensitization and her laboratory is actively pursuing pharmacological candidates to improve the safety and efficacy of desensitizations. She has pioneered the diagnosis and treatment of mast cell activation disorders and mastocytosis and is the PI of clinical trials with Tyrosine Kinase Inhibitors.

Dr. Castells served on the Board of Directors of The American Academy of Allergy, Asthma & Immunology (AAAAI), and is now the research chair of the AAAAI Foundation. She is on the Board of Directors for the ABAI, has been at the Editorial Board of the Journal of Allergy and Clinical Immunology (JACI), the JACI In Practice and Annals of Allergy, Asthma and Immunology. She has served at the council of the Collegium Internationale Allergologicum and directs the International Drug Desensitization Meeting (DDIM) in Barcelona, Spain, yearly.

Dr. Castells can be reached at mcastells@bwh.harvard.edu.

Mark P. Jarrett, MD, MBA, MS

Senior Vice President and Chief Quality Officer, Northwell Health; Deputy Chief Medical Officer, Northwell Health; Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; East Garden City, NY



As chief quality officer for Northwell Health, Dr. Jarrett is responsible for system-wide initiatives in quality and safety. As the Chair of the Clinical Advisory Group, he oversees Northwell's COVID-19 efforts, including clinical protocols, clinical operational decisions, and system-wide planning for 23 hospitals, 800 ambulatory sites, 15,000 providers and 74,000 team members.

Dr. Jarrett is also Northwell's deputy chief medical officer and a professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

He previously served as chief medical officer and DIO at Staten Island University Hospital (SIUH). Prior to that appointment, Dr. Jarrett was director of Rheumatology at SIUH from 1982-1999. Dr. Jarrett has extensive research experience and has been published on the subject of the immune response in systemic lupus erythematosus, quality and cybersecurity in health care.

Dr. Jarrett is board certified in internal medicine and rheumatology. He is a Fellow of the American College of Physicians and the American College of Rheumatology, and past president of the Richmond County Medical Society.

Dr. Jarrett earned his medical degree from New York University School of Medicine. He completed his residency in internal medicine at Montefiore Medical Center, and a fellowship at Montefiore Medical Center and Albert Einstein College of Medicine.

Dr. Jarrett also holds an MBA from Wagner College and an MS in Medical Informatics from Northwestern University. He is also a certified Healthcare Information Security and Privacy Practitioner (HCISPP).

Dr. Jarrett can be reached at MJarrett@northwell.edu

Michael D. Keller, MD

Associate Professor, Division of Allergy / Immunology; Director, Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency Disorders; Washington, DC



Michael Keller, M.D., is a pediatric immunologist at Children's National Hospital and specializes in the diagnosis and treatment of primary and secondary immunodeficiency disorders. Dr. Keller is on the Children's National COVID-19 research committee, and his laboratory led a study on T-cell responses to SARS-CoV-2 in patients in the DC region which was recently published in *Blood*.

He has authored many peer-reviewed articles and contributed to expert consensus guidelines on the treatment and diagnosis of primary immunodeficiency disorders. Dr. Keller is a member of the American Academy of Allergy, Asthma, and Immunology (AAAAI); the Clinical Immunology Society; the European Society of Immunodeficiency; and the Primary Immunodeficiency Treatment Consortium (PIDTC).

Dr. Keller's research focuses on the use of adoptive T-cell therapies for treatment of infections in immunocompromised patients, including the use of this therapy to improve outcomes in children with primary immunodeficiency disorders as well as those undergoing bone marrow transplantation for cancer. He is the primary investigator of several Phase I-II studies of virus-specific T-cell immunotherapy.

Dr. Keller can be reached at MKeller@childrensnational.org

Nancy Kramer RN, BSN, CRNI

VP Clinical Nursing, Optum Infusion Services; Lenexa, KS



Nancy Kramer is a Vice President of Clinical Nursing who works with Optum Infusion Pharmacy to support the safe and effective delivery of infusion therapy services to patients in the comfort of their home.

Nancy believes that home infusion offers an important site of care option for patients living with acute and chronic conditions and the families who care for them.

Nancy has worked in positions of progressive nursing leadership with national home infusion providers and published the first survey of home infusion provider data while serving as the VP of Clinical Affairs for the National Home Infusion Association. She has written and presented extensively on a wide range of topics related to infusion nursing services and regulatory considerations and has maintained an infusion nursing certification (CRNI) from the Infusion Nurses Society for 14+ years.

Nancy can be reached at Nkramer@optum.com.

Madhumita Murphy, MD, MSCI, MBA

Senior Medical Advisor, Eli Lilly and Company; Franklin, TN



Dr. Murphy comes to Lilly with many experiences as a medical professional and medical leader. Prior to coming to Lilly, Madhu practiced medicine at the Monroe Carell Jr. Children's Hospital at Vanderbilt, in Nashville, Tennessee, where she also served as Assistant Professor of Pediatrics. Madhu is a physician with extensive experience in general pediatrics and pediatric cardiac intensive care. In her various leadership capacities, Madhu led a multi-disciplinary team of fellows, designed and launched a primary intensivist program and has led efforts to improve the overall wellness, efficiency and productivity of physicians. Previously, Madhu has also designed and performed clinical trials to test vaccines. Madhu also worked for the Walter Reed Army Medical Center in Washington, DC and the Bassett Army Community Fairbanks Memorial Hospital in Fairbanks, Alaska, where she cared for dependent children of soldiers in remote military and civilian community hospitals and where she received the Army Commendation Medal.

Ernesto Oviedo-Orta, MD, PhD, MBA

Senior Director, Medical Affairs, Regeneron Pharmaceuticals, Inc.; Tarrytown, NY



Dr. Oviedo-Orta graduated as MD in Havana, Cuba where he also completed his residency in Clinical Immunology. He obtained his PhD in Medical Biochemistry and Immunology at the University of Wales College of Medicine in Cardiff, UK followed by a postdoctoral fellowship at Bristol University before becoming Assistant Professor of Immunology at the University of Surrey in England, UK. He then joined the pharmaceutical industry where he has worked for various companies including Novartis Vaccines, GSK, Sanofi Pasteur, Celgene Co. and Bristol Myers Squibb. Dr Oviedo Orta has more than 20 years of experience in R&D in Infectious Diseases and joined Regeneron Pharmaceuticals October last year as Infectious Disease Lead in Medical Affairs.
